Hereditary haemochromatosis and hepatocellular carcinoma in males: A strategy for estimating the potential for primary prevention

Journal of Medical Screening

Volumn 10, Issue 1, 2003, Pages 11-13

  Haddow, James E ^a   Palomaki, Glenn E ^a   McClain, Monica ^a   Craig, Wendy ^a  

^a FOUNDATION FOR BLOOD RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DNA DETERMINATION; FEASIBILITY STUDY; GENE MUTATION; HEMOCHROMATOSIS; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; INFORMATION CENTER; INFORMATION PROCESSING; LIFE TABLE; LIVER BIOPSY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; ONSET AGE; PRIMARY PREVENTION; RISK ASSESSMENT;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; HEMOCHROMATOSIS; HUMANS; LIFE TABLES; LIVER NEOPLASMS; MALE; MIDDLE AGED; PRIMARY PREVENTION; SEX CHARACTERISTICS; UNITED STATES;

EID: 0038705075     PISSN: 09691413     EISSN: None     Source Type: Journal    
DOI: 10.1258/096914103321610743     Document Type: Article

References (13)

1. McCullen MA, Crawford DHG, Hickman PE. Screening for hemochromatosis. Clin Chim Acta 2002;315:169-86.
2. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G→A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002;359:211-18.
3. Hanson EH, Imperatore G, Burke W. HFE gene and hereditary hemochromatosis: a HuGE review. Am J Epidemol 2001;154:193-206.
4. Bulaj ZJ, Ajioka RS, Phillips JD, et al. Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med 2000;343:1529-35.
5. Asberg A, Hveem K, Thorstensen K, et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol 2001;36:1108-15.
6. National Vital Statistics Report. Vol. 50, No. 6, 21 March 2002: 15-16.
7. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J, eds. Cancer incidence in five continents, Vol. VII (IARC Scientific Publications No. 143). Lyon: IARC, 1997.
8. Willis G, Wimperis JZ, Lonsdale R, et al. Incidence of liver disease in people with HFE mutations. Gut 2000;46:401-4.
9. Yang Q, McDonnell SM, Khoury MJ, Cono J, Parrish G. Hemochromatosis-associated mortality in the United States from 1979 to 1992: an analysis of multiple cause mortality data. Ann Intern Med 1998;129:946-53.
10. Fargion S, Stazi MA, Francanzani AL, et al. Mutations in the HFE gene and their interaction with exogenous risk factors in hepatocellular carcinoma. Blood Cells Mol Dis 2001;27:505-11.
11. Fletcher LM, Dixon JL, Purdie DM, et al. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology 2002;122:281-9.
12. Blanc JF, DeLedinghen V, Bernard PH, et al. Increased incidence of HFE C282Y mutations in patients with iron overload and hepatocellular carcinoma developed in non-cirrhotic liver. J Hepatol 2000;32:805-11.
13. Distante S, Berg JP, Lande K, et al. High prevalence of the hemochromatosis-associated Cys282Tyr HFE gene mutation in a healthy Norwegian population in the city of Oslo, and its phenotypic expression. Scand J Gastroenterol 1999;34:529-34.